Krystal Biotech Receives FDA Approval for the First-Ever Redosable Gene Therapy,…
<!-- Name:DistributionId Value:8843111 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
Browsing Tag
Dystrophic
Krystal Biotech Receives Positive Opinion from EMA Pediatric Committee on the…
• Company on track to submit European marketing application in Q4 2022 • No additional studies required PITTSBURGH, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the…
FDA Accepts Krystal Biotech’s Biologics License Application for Dystrophic…
FDA granted Priority Review designationPDUFA target action date is February 17, 2023FDA stated that it is not currently planning to hold an advisory committee meeting PITTSBURGH, Aug.…
Krystal Biotech Announces Completion of the GEM-3 Pivotal Phase 3 Study Evaluating…
Topline results anticipated in the fourth quarter of 2021Of the 31 patients enrolled in the trial, 29 patients completed the study with no missing visits, including the three primary…
Abeona Therapeutics Activates Second Clinical Trial Site in EB-101 Pivotal Phase 3…
NEW YORK and CLEVELAND, July 23, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced the activation of a…
DelveInsight Highlights Major Advances, Transformative Therapies and Leading Players…
Los Angeles, USA, June 30, 2021 (GLOBE NEWSWIRE) -- DelveInsight Highlights Major Advances, Transformative Therapies and Leading Players Wheeling the Dystrophic Epidermolysis Bullosa…